Detalhe da pesquisa
1.
Targeting TRIM37-driven centrosome dysfunction in 17q23-amplified breast cancer.
Nature
; 585(7825): 447-452, 2020 09.
Artigo
Inglês
| MEDLINE | ID: mdl-32908313
2.
Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer.
N Engl J Med
; 384(25): 2394-2405, 2021 06 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34081848
3.
Adjuvant Olaparib in BRCA-Mutated Breast Cancer. Reply.
N Engl J Med
; 385(15): 1440, 2021 10 07.
Artigo
Inglês
| MEDLINE | ID: mdl-34614338
4.
Functional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancer.
J Pathol
; 241(3): 350-361, 2017 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-27859262
5.
Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.
Annu Rev Med
; 66: 455-70, 2015.
Artigo
Inglês
| MEDLINE | ID: mdl-25341009
6.
Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.
Cancer Cell
; 13(2): 91-104, 2008 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-18242510
7.
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Breast Cancer Res
; 16(3): 211, 2014 Jun 03.
Artigo
Inglês
| MEDLINE | ID: mdl-25093514
8.
AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody.
Allergy
; 74(10): 1985-1989, 2019 10.
Artigo
Inglês
| MEDLINE | ID: mdl-30964550
9.
Engineering and stable production of recombinant IgE for cancer immunotherapy and AllergoOncology.
J Allergy Clin Immunol
; 141(4): 1519-1523.e9, 2018 04.
Artigo
Inglês
| MEDLINE | ID: mdl-29360527
10.
Cancer-associated FBXW7 loss is synthetic lethal with pharmacological targeting of CDC7.
Mol Oncol
; 18(2): 369-385, 2024 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-37866880
11.
Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth.
Clin Cancer Res
; 2024 May 21.
Artigo
Inglês
| MEDLINE | ID: mdl-38772416
12.
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.
J Clin Oncol
; 42(11): 1288-1300, 2024 Apr 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38301187
13.
Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles.
Mod Pathol
; 26(7): 955-66, 2013 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-23392436
14.
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
Proc Natl Acad Sci U S A
; 107(22): 10208-13, 2010 Jun 01.
Artigo
Inglês
| MEDLINE | ID: mdl-20479250
15.
Systemic Therapy for Hereditary Breast Cancers.
Hematol Oncol Clin North Am
; 37(1): 203-224, 2023 02.
Artigo
Inglês
| MEDLINE | ID: mdl-36435611
16.
Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype.
Nat Commun
; 14(1): 7408, 2023 11 16.
Artigo
Inglês
| MEDLINE | ID: mdl-37973922
17.
A HUWE1 defect causes PARP inhibitor resistance by modulating the BRCA1-∆11q splice variant.
Oncogene
; 42(36): 2701-2709, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37491606
18.
MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells.
Cell Rep
; 42(5): 112484, 2023 05 30.
Artigo
Inglês
| MEDLINE | ID: mdl-37163373
19.
Platinum chemotherapy for BRCA1-related breast cancer: do we need more evidence?
Breast Cancer Res
; 14(6): 115, 2012 Nov 13.
Artigo
Inglês
| MEDLINE | ID: mdl-23146216
20.
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.
EMBO J
; 27(9): 1368-77, 2008 May 07.
Artigo
Inglês
| MEDLINE | ID: mdl-18388863